Advanced search
Publication Cover
Therapeutic Delivery Volume 3, 2012 - Issue 9
Submit an article Journal homepage
98
Views
1
CrossRef citations to date
0
Altmetric
Review

Emerging Nanodelivery Strategies of RNAi Molecules for Colon Cancer Therapy: Preclinical Developments

Ziyad Binkhathlana Nanomedicine Research Unit Department of Pharmaceutics College of Pharmacy King Saud UniversitySaudi Arabia
&
Aws Alshamsanb Nanomedicine Research Unit Department of Pharmaceutics College of Pharmacy King Saud UniversitySaudi [email protected]
Pages 1117-1130 | Published online: 29 Aug 2012

References

  • Temple LK . The prognosis of colon cancer is dependent on accurate staging. J. Surg. Oncol.102(1), 1–2 (2010).
  • Tannock IF . Conventional cancer therapy: promise broken or promise delayed? Lancet351(Suppl. 2), SII9–SII16 (1998).
  • Ghetie C , DaviesM, CornfeldD, SuhN, SaifMW. Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin. Colorectal Cancer7(4), 283–286 (2008).
  • Wong TW , ColomboG, SonvicoF. Pectin matrix as oral drug delivery vehicle for colon cancer treatment. AAPS PharmSciTech12(1), 201–214 (2011).
  • Kinget R , KalalaW, VervoortL, van den Mooter G. Colonic drug targeting. J. Drug Target6(2), 129–149 (1998).
  • Jose S , PremaMT, ChackoAJ, ThomasAC, SoutoEB. Colon specific chitosan microspheres for chronotherapy of chronic stable angina. Colloids Surf. B Biointerfaces83(2), 277–283 (2011).
  • Kadam VD , GattaniSG. Development of colon targeted multiparticulate pulsatile drug delivery system for treating nocturnal asthma. Drug Deliv.17(5), 343–351 (2010).
  • Chourasia MK , JainSK. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci.6(1), 33–66 (2003).
  • Stevens HN , WilsonCG, WellingPGet al. Evaluation of Pulsincap to provide regional delivery of dofetilide to the human GI tract. Int. J. Pharm. 236(1–2), 27–34 (2002).
  • Fukui E , MiyamuraN, UemuraK, KobayashiM. Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int. J. Pharm.204(1–2), 7–15 (2000).
  • Li J , YangL, FergusonSMet al. In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES) in multi-pH media using United States Pharmacopeia apparatus II and III. AAPS PharmSciTech3(4), E33 (2002).
  • Bromberg L . Polymeric micelles in oral chemotherapy. J. Control. Release128(2), 99–112 (2008).
  • Cantore M , CapparelliE, BerardiF, PerroneR, ColabufoNA. Clinical pharmacokinetic and metabolism of PET radiotracers for imaging P-glycoprotein in chemoresistant tumor of colorectal cancer. Curr. Drug Metab.12(10), 985–988 (2011).
  • Juliano RL , LingV. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta455(1), 152–162 (1976).
  • Kuppens IE , BreedveldP, BeijnenJH, SchellensJH. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest.23(5), 443–464 (2005).
  • Sparreboom A , NooterK. Does P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resist. Update3(6), 357–363 (2000).
  • Cordon-Cardo C , O‘BrienJP, CasalsDet al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc. Natl Acad. Sci. USA 86(2), 695–698 (1989).
  • Ho RH , KimRB. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther.78(3), 260–277 (2005).
  • Thiebaut F , TsuruoT, HamadaH, GottesmanMM, PastanI, WillinghamMC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA84(21), 7735–7738 (1987).
  • Goldstein LJ , GalskiH, FojoAet al. Expression of a multidrug resistance gene in human cancers. J. Natl Cancer Inst. 81(2), 116–124 (1989).
  • Weinstein RS , JakateSM, DominguezJMet al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 51(10), 2720–2726 (1991).
  • Ford JM , HaitWN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev.42(3), 155–199 (1990).
  • Ford JM , HaitWN. Pharmacologic circumvention of multidrug resistance. Cytotechnology12(1–3), 171–212 (1993).
  • Wang SW , MonagleJ, McNultyC, PutnamD, ChenH. Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J. Pharm. Sci.93(11), 2755–2767 (2004).
  • Watanabe T , NakayamaY, NaitoM, Oh-haraT, ItohY, TsuruoT. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Anticancer Drugs7(8), 825–832 (1996).
  • Krishna R , MayerLD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci.11(4), 265–283 (2000).
  • Lampidis TJ , KrishanA, PlanasL, TapieroH. Reversal of intrinsic resistance to adriamycin in normal cells by verapamil. Cancer Drug Deliv.3(4), 251–259 (1986).
  • Alaoui-Jamali MA , SchecterRL, RustumYM, CenturioniMG, LehnertS, BatistG. In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11–2933. J. Pharmacol. Exp. Ther.264(3), 1299–1304 (1993).
  • Boesch D , MullerK, Pourtier-ManzanedoA, LoorF. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res.196(1), 26–32 (1991).
  • Krishna R , de Jong G, Mayer LD. Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin. Anticancer Res.17(5A), 3329–3334 (1997).
  • Dale IL , TuffleyW, CallaghanRet al. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br. J. Cancer 78(7), 885–892 (1998).
  • Dantzig AH , ShepardRL, CaoJet al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56(18), 4171–4179 (1996).
  • Peck RA , HewettJ, HardingMWet al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol. 19(12), 3130–3141 (2001).
  • Baguley BC . Multiple drug resistance mechanisms in cancer. Mol. Biotechnol.46(3), 308–316.
  • Fletcher JI , HaberM, HendersonMJ, NorrisMD. ABC transporters in cancer: more than just drug efflux pumps. Nature Rev. Cancer10(2), 147–156 (2010).
  • Szakacs G , PatersonJK, LudwigJA, Booth-GentheC, GottesmanMM. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov.5(3), 219–234 (2006).
  • Quattrone A , PapucciL, MorgantiMet al. Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance. Oncol. Res. 6(7), 311–320 (1994).
  • Nagata J , KijimaH, HatanakaHet al. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. Int. J. Oncol. 21(5), 1021–1026 (2002).
  • Qia S , WangH, ChenX. Reversal of HCC drug resistance by using hammerhead ribozymes against multidrug resistance 1 gene. J. Huazhong Univ. Sci. Technol. Med. Sci.25(6), 662–664 (2005).
  • Elbashir SM , HarborthJ, LendeckelW, YalcinA, WeberK, TuschlT. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature411(6836), 494–498 (2001).
  • Elbashir SM , LendeckelW, TuschlT. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Devel.15(2), 188–200 (2001).
  • Xia Z , ZhuZ, ZhangLet al. Specific reversal of MDR1/P-gp-dependent multidrug resistance by RNA interference in colon cancer cells. Oncol. Reports 20(6), 1433–1439 (2008).
  • Liu C , ZhaoG, LiuJet al. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J. Control. Release 140(3), 277–283 (2009).
  • Matsui Y , KobayashiN, NishikawaM, TakakuraY. Sequence-specific suppression of mdr1a/1b expression in mice via RNA interference. Pharm. Res.22(12), 2091–2098 (2005).
  • Donmez Y , GunduzU. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed. Pharmacother.65(2), 85–89 (2011).
  • Pakunlu RI , WangY, SaadM, KhandareJJ, StarovoytovV, MinkoT. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J. Control. Release114(2), 153–162 (2006).
  • Alahari SK , DeanNM, FisherMHet al. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5´ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 50(4), 808–819 (1996).
  • Poole EM , CurtinK, HsuLet al. Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer. Int. J. Mol. Epidemiol. Genetics 2(4), 300–315 (2011).
  • Yarden Y . Biology of HER2 and its importance in breast cancer. Oncology61(Suppl. 2), 1–13 (2001).
  • Lee D , YuM, LeeEet al. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J. Clin. Investig. 119(9), 2702–2713 (2009).
  • Yotsumoto F , YagiH, SuzukiSOet al. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem. Biophys. Res. Comm. 365(3), 555–561 (2008).
  • Firestein R , BassAJ, KimSYet al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455(7212), 547–551 (2008).
  • He SB , YuanY, WangL, YuMJ, ZhuYB, ZhuXG. Effects of cyclin-dependent kinase 8 specific siRNA on the proliferation and apoptosis of colon cancer cells. J. Exp. Clin. Cancer Res.30, 109 (2011).
  • Oh BY , LeeRA, KimKH. siRNA targeting Livin decreases tumor in a xenograft model for colon cancer. World J. Gastroenterol.17(20), 2563–2571 (2011).
  • Subramaniam V , VincentIR, GilakjanM, JothyS. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp. Mol. Pathol.83(3), 332–340 (2007).
  • Banchereau J , SteinmanRM. Dendritic cells and the control of immunity. Nature392(6673), 245–252 (1998).
  • Stockwin LH , McGonagleD, MartinIG, BlairGE. Dendritic cells: immunological sentinels with a central role in health and disease. Immunol. Cell Biol.78(2), 91–102 (2000).
  • Shortman K , LiuYJ. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol.2(3), 151–161 (2002).
  • Steinman RM , BanchereauJ. Taking dendritic cells into medicine. Nature449(7161), 419–426 (2007).
  • Steinman RM . Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system. Nat. Med.13(10), 1155–1159 (2007).
  • Kalinski P , HilkensCM, WierengaEA, KapsenbergML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today20(12), 561–567 (1999).
  • Trombetta ES , MellmanI. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol.23, 975–1028 (2005).
  • Yang L , CarboneDP. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res.92, 13–27 (2004).
  • Alshamsan A . Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma. Immunopharmacol. Immunotoxicol.34(3), 465–469 (2011).
  • Alshamsan A , HamdyS, HaddadiAet al. STAT3 knockdown in B16 melanoma by siRNA lipopolyplexes induces bystander immune response in vitro and in vivo. Translational Oncol. 4(3), 178–188 (2011).
  • Alshamsan A , HaddadiA, HamdySet al. STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response. Mol. Pharm. 7(5), 1643–1654 (2010).
  • Alshamsan A , HamdyS, SamuelJ, El-KadiAO, LavasanifarA, UludagH. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials31(6), 1420–1428 (2010).
  • Munn DH , SharmaMD, HouDet al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Investig. 114(2), 280–290 (2004).
  • Sharma MD , BabanB, ChandlerPet al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Investig. 117(9), 2570–2582 (2007).
  • Yen MC , LinCC, ChenYLet al. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin. Cancer Res. 15(2), 641–649 (2009).
  • Whitehead KA , LangerR, AndersonDG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov.8(2), 129–138 (2009).
  • Hu CM , ChangZF. Synthetic lethality by lentiviral short hairpin RNA silencing of thymidylate kinase and doxorubicin in colon cancer cells regardless of the p53 status. Cancer Res.68(8), 2831–2840 (2008).
  • Fichtner-Feigl S , TerabeM, KitaniAet al. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res. 68(9), 3467–3475 (2008).
  • Muruve DA . The innate immune response to adenovirus vectors. Hum. Gene Ther.15(12), 1157–1166 (2004).
  • Zaiss AK , MuruveDA. Immune responses to adeno-associated virus vectors. Curr. Gene Ther.5(3), 323–331 (2005).
  • Kohn DB , SadelainM, GloriosoJC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer3(7), 477–488 (2003).
  • Uprichard SL . The therapeutic potential of RNA interference. FEBS Lett.579(26), 5996–6007 (2005).
  • Kennedy D . Breakthrough of the year. Science298(5602), 2283 (2002).
  • Behlke MA . Progress towards in vivo use of siRNAs. Mol. Ther.13(4), 644–670 (2006).
  • Grayson AC , DoodyAM, PutnamD. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm. Res.23(8), 1868–1876 (2006).
  • Li SD , ChonoS, HuangL. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J. Control. Release126(1), 77–84 (2008).
  • Kim SH , JeongJH, LeeSH, KimSW, ParkTG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release129(2), 107–116 (2008).
  • Kim WJ , ChangCW, LeeM, KimSW. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J. Control. Release118(3), 357–363 (2007).
  • Kramer M , StumbeJF, GrimmGet al. Dendritic polyamines: simple access to new materials with defined treelike structures for application in nonviral gene delivery. Chembiochem 5(8), 1081–1087 (2004).
  • Christian DA , CaiS, BowenDM, KimY, PajerowskiJD, DischerDE. Polymersome carriers: from self-assembly to siRNA and protein therapeutics. Eur. J. Pharm. Biopharm.71(3), 463–474 (2009).
  • Jensen DM , CunD, MaltesenMJ, FrokjaerS, NielsenHM, FogedC. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J. Control. Release (2009).
  • Godbey WT , WuKK, MikosAG. Poly(ethylenimine) and its role in gene delivery. J. Control. Release60(2–3), 149–160 (1999).
  • Boussif O , Lezoualc‘hF, ZantaMAet al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92(16), 7297–7301 (1995).
  • Demeneix B , BehrJP. Polyethylenimine (PEI). Adv. Genet.53, 217–230 (2005).
  • Bologna JC , DornG, NattF, WeilerJ. Linear polyethylenimine as a tool for comparative studies of antisense and short double-stranded RNA oligonucleotides. Nucleosides Nucleotides Nucleic Acids22(5–8), 1729–1731 (2003).
  • Urban-Klein B , WerthS, AbuharbeidS, CzubaykoF, AignerA. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther.12(5), 461–466 (2005).
  • Aigner A . Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J. Biotechnol.124(1), 12–25 (2006).
  • Grzelinski M , Urban-KleinB, MartensTet al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 17(7), 751–766 (2006).
  • Kim SH , JeongJH, LeeSH, KimSW, ParkTG. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release116(2), 123–129 (2006).
  • Kaestner P , AignerA, BastiansH. Therapeutic targeting of the mitotic spindle checkpoint through nanoparticle-mediated siRNA delivery inhibits tumor growth in vivo. Cancer Lett.304(2), 128–136 (2011).
  • Ibrahim AF , WeirauchU, ThomasM, GrunwellerA, HartmannRK, AignerA. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res.71(15), 5214–5224 (2011).
  • Torchilin VP . Multifunctional nanocarriers. Adv. Drug Deliv. Rev.58(14), 1532–1555 (2006).
  • Zhang X , GeYL, TianRH. The knockdown of c-myc expression by RNAi inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo. Cell. Mol. Biol. Lett.14(2), 305–318 (2009).
  • Peer D , ParkEJ, MorishitaY, CarmanCV, ShimaokaM. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science319(5863), 627–630 (2008).
  • Wilson DS , DalmassoG, WangL, SitaramanSV, MerlinD, MurthyN. Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater.9(11), 923–928 (2010).
  • Zhang H . Survivin specified small interfering RNA-CLIO-Cy5.5. In: Molecular Imaging and Contrast Agent Database (MICAD). National Center for Biotechnology Information, Bethesda, MD, USA (2004).
  • Abedini F , IsmailM, HosseinkhaniHet al. Effects of CXCR4 siRNA/dextran-spermine nanoparticles on CXCR4 expression and serum LDH levels in a mouse model of colorectal cancer metastasis to the liver. Cancer Manag. Res. 3, 301–309 (2011).
  • Leng A , YangJ, LiuTet al. Nanoparticle-delivered VEGF-silencing cassette and suicide gene expression cassettes inhibit colon carcinoma growth in vitro and in vivo. Tumour Biol. 32(6), 1103–1111 (2011).
  • Kim WJ , ChristensenLV, JoSet al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol. Ther. 14(3), 343–350 (2006).
  • Krieger ML , KonoldA, WieseM, JaehdeU, BendasG. Targeted doxorubicin-liposomes as a tool to circumvent P-gp-mediated resistance in ovarian carcinoma cells. Int. J. Clin. Pharmacol. Ther.48(7), 442–444 (2010).
  • Thierry AR , DritschiloA, RahmanA. Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem. Biophys. Res. Commun.187(2), 1098–1105 (1992).
  • Li X , LuWL, LiangGWet al. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice. Eur. J. Clin. Invest. 36(6), 409–418 (2006).
  • Wang J , GohB, LuWet al. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol. Pharm. Bull.28(5), 822–828 (2005).
  • Wu J , LuY, LeeAet al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 10(3), 350–357 (2007).
  • Alakhov V , MoskalevaE, BatrakovaEV, KabanovAV. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug. Chem.7(2), 209–216 (1996).
  • Venne A , LiS, MandevilleR, KabanovA, AlakhovV. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res.56(16), 3626–3629 (1996).
  • Alakhov V , KlinskiE, LiSet al. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf. B Biointerfaces 16(1–4), 113–134 (1999).
  • Elamanchili P , McEachernC, BurtH. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function. J. Pharm. Sci.98(3), 945–958 (2009).
  • Batrakova EV , LiS, AlakhovVY, MillerDW, KabanovAV. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther.304(2), 845–854 (2003).
  • Astier A , DoatB, FerrerMJet al. Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells. Cancer Res. 48(7), 1835–1841 (1988).
  • Omelyanenko V , KopeckovaP, GentryC, KopecekJ. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control. Release53(1–3), 25–37 (1998).
  • Hu CM , ZhangL. Therapeutic nanoparticles to combat cancer drug resistance. Curr. Drug Metab.10(8), 836–841 (2009).
  • de Verdiere AC , DubernetC, NematiFet al. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer 76(2), 198–205 (1997).
  • Pepin X , AttaliL, DomraultCet al. On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. J. Chromatogr. B Biomed. Sci. Appl. 702(1–2), 181–191 (1997).
  • Kopecek J , KopeckovaP, MinkoT, LuZ. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm.50(1), 61–81 (2000).
  • Dong X , MumperRJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond.)5(4), 597–615 (2010).
  • Shapira A , LivneyYD, BroxtermanHJ, AssarafYG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat.14(3), 150–163 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.